| Entry |
|
|---|
| Name |
Fluvoxamine (INN) |
|---|
| Formula |
C15H21F3N2O2
|
|---|
| Exact mass |
318.1555
|
|---|
| Mol weight |
318.33
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG01643 CYP2C9 inhibitor
DG01933 CYP2C19 inhibitor
DG01645 CYP2D6 inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
|
|---|
| Remark |
| Product (DG00946): | D00824<JP/US> |
|
|---|
| Efficacy |
Antidepressant, Selective serotonin reuptake inhibitor (SSRI) |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
CYP inhibition: CYP1A2 [HSA: 1544], CYP2C19 [HSA: 1557]; CYP2C9 [HSA: 1559], CYP2D6 [HSA: 1565], CYP3A4 [HSA: 1576]
|
|---|
| Structure map |
| map07234 | Neurotransmitter transporter inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06A ANTIDEPRESSANTS
N06AB Selective serotonin reuptake inhibitors
N06AB08 Fluvoxamine
D07984 Fluvoxamine (INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
DG00946 Fluvoxamine
D07984 Fluvoxamine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00946 Fluvoxamine
D07984 Fluvoxamine
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG00946 Fluvoxamine
D07984 Fluvoxamine
DG01643 CYP2C9 inhibitor
DG00946 Fluvoxamine
D07984 Fluvoxamine
DG01933 CYP2C19 inhibitor
DG00946 Fluvoxamine
D07984 Fluvoxamine
DG01645 CYP2D6 inhibitor
DG00946 Fluvoxamine
D07984 Fluvoxamine
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG00946 Fluvoxamine
D07984 Fluvoxamine
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A4 (HTT)
D07984 Fluvoxamine (INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D07984
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
DG00946 Fluvoxamine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00946 Fluvoxamine
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG00946 Fluvoxamine
DG01643 CYP2C9 inhibitor
DG00946 Fluvoxamine
DG01933 CYP2C19 inhibitor
DG00946 Fluvoxamine
DG01645 CYP2D6 inhibitor
DG00946 Fluvoxamine
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG00946 Fluvoxamine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 22
1 C8y C 19.9500 -16.8000
2 C8x C 19.9500 -18.2000
3 C8x C 21.1400 -18.9000
4 C8y C 22.4000 -18.2000
5 C8x C 22.4000 -16.8000
6 C8x C 21.1400 -16.1000
7 C1d C 18.7600 -16.1000
8 X F 17.5000 -15.4000
9 X F 19.3900 -14.8400
10 X F 18.1300 -17.3600
11 C2c C 23.5900 -18.9000
12 C1b C 24.8500 -18.2000
13 N2b N 23.5900 -20.3000
14 O2a O 24.8500 -21.0000
15 C1b C 26.0400 -20.3000
16 C1b C 27.2300 -21.0000
17 N1a N 28.4200 -20.3000
18 C1b C 25.9700 -18.9000
19 C1b C 27.2300 -18.2000
20 C1b C 28.4200 -18.9000
21 O2a O 29.6100 -18.2000
22 C1a C 30.8000 -18.9000
BOND 22
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 7 8 1
9 7 9 1
10 7 10 1
11 4 11 1
12 11 12 1
13 11 13 2
14 13 14 1
15 14 15 1
16 15 16 1
17 16 17 1
18 12 18 1
19 18 19 1
20 19 20 1
21 20 21 1
22 21 22 1
|
|---|